Regeneron Pharmaceuticals Inc.

URI: https://gptkb.org/entity/Regeneron_Pharmaceuticals_Inc.
GPTKB entity
Statements (50)
Predicate Object
gptkbp:instanceOf gptkb:biotechnology
gptkb:public_company
gptkbp:awarded gptkb:award
gptkbp:CEO gptkb:Leonard_Schleifer
gptkbp:collaboratedWith gptkb:Bayer
gptkb:Sanofi
gptkbp:country gptkb:United_States
gptkbp:developedTreatmentFor gptkb:COVID-19
gptkb:atopic_dermatitis
asthma
high cholesterol
age-related macular degeneration
rheumatoid arthritis
gptkbp:focusArea immunology
infectious diseases
oncology
ophthalmology
rare diseases
gptkbp:foundedBy gptkb:George_Yancopoulos
gptkb:Leonard_Schleifer
gptkbp:foundedYear 1988
gptkbp:hasPatent gptkb:VelocImmune_technology
gptkb:VelociGene_technology
monoclonal antibody technology
gptkbp:hasResearchCenter gptkb:Tarrytown,_New_York
gptkbp:headquartersLocation gptkb:Tarrytown,_New_York,_United_States
https://www.w3.org/2000/01/rdf-schema#label Regeneron Pharmaceuticals Inc.
gptkbp:industry gptkb:biotechnology
gptkbp:ISIN US75886F1075
gptkbp:listedOn gptkb:NASDAQ
gptkbp:mainActivity drug discovery
drug development
drug commercialization
gptkbp:manufacturingFacilities gptkb:Rensselaer,_New_York
gptkbp:memberOf gptkb:S&P_500
gptkbp:netIncome $4.2 billion (2022)
gptkbp:notableProduct gptkb:EYLEA
gptkb:REGEN-COV
gptkb:Dupixent
gptkb:Kevzara
gptkb:Praluent
gptkbp:numberOfEmployees ~11,800 (2023)
gptkbp:president gptkb:George_Yancopoulos
gptkbp:revenue $12.2 billion (2022)
gptkbp:stockSymbol gptkb:REGN
gptkbp:subsidiary gptkb:Regeneron_Ireland
gptkbp:tradedOn gptkb:NASDAQ:_REGN
gptkbp:website https://www.regeneron.com/
gptkbp:bfsParent gptkb:^NDX
gptkbp:bfsLayer 6